Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Petrucci, Maria Teresa  [Clear All Filters]
2023
Mina R, Petrucci MTeresa, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, Mengarelli A, Spadaro A, Lisi C, Curci P, et al. A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents. Haematologica. 2023.
2021
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, et al. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol. 2021.
2020
Tacchetti P, Pantani L, Patriarca F, Petrucci MTeresa, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020;7(12):e861-e873.
2014
Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MTeresa, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, et al. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2014;371(10):895-905.
Bringhen S, Petrucci MTeresa, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014.